Kite and HiFiBio Signs a Research & License Agreement for Neoantigen-Reactive T Cell Receptors (TCRs)
Shots:
- The collaboration is focused on developing technology for neoantigen-reactive T cell receptors (TCRs) to treat cancers- including solid tumor
- HiFiBio to get an upfront $10M with additional milestones payments and Kite will hold an exclusive option to license HiFiBiO’s single cell technology platform
- HiFiBio Therapeutics is focused on activating human immune system to fight diseases. It is using its single-cell profiling technology to treat cancer and autoimmune disorder
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
